Steven Cohen’s Corvus Pharmaceuticals CRVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.01M Buy
+435,146
New +$6.06M 0.01% 1809
2026
Q1
– Sell
-2,875,000
Closed -$22.1M – 3890
2025
Q4
$22.1M Sell
2,875,000
-3,579,274
-55% -$28.2M 0.02% 816
2025
Q3
$47.6M Sell
6,454,274
-588,099
-8% -$3.01M 0.08% 279
2025
Q2
$28.2M Buy
7,042,373
+4,254,742
+153% +$15.5M 0.06% 386
2025
Q1
$8.86M Sell
2,787,631
-242,380
-8% -$1.14M 0.02% 728
2024
Q4
$16.2M Sell
3,030,011
-2,532,718
-46% -$18.9M 0.04% 531
2024
Q3
$29.4M Sell
5,562,729
-401,781
-7% -$1.44M 0.07% 310
2024
Q2
$10.9M Buy
+5,964,510
New +$11.1M 0.03% 578
2022
Q2
– Sell
-745,000
Closed -$1.22M – 1434
2022
Q1
$1.22M Sell
745,000
-50,000
-6% -$91.5K ﹤0.01% 935
2021
Q4
$1.92M Buy
795,000
+220,000
+38% +$853K 0.01% 827
2021
Q3
$2.78M Buy
+575,000
New +$1.7M 0.01% 753
2017
Q4
– Sell
-195,034
Closed -$3.11M – 924
2017
Q3
$3.11M Sell
195,034
-37,349
-16% -$517K 0.01% 617
2017
Q2
$2.81M Sell
232,383
-175,894
-43% -$1.88M 0.02% 596
2017
Q1
$8.48M Buy
+408,277
New +$6.4M 0.05% 431

Other funds holding CRVS

Steven Cohen's CRVS Position: Q3 2026 in Review

Steven Cohen opened a new position in Corvus Pharmaceuticals (CRVS) in Q3 2026: 435,146 shares worth $5.01M. The stake represents 0.01% of the portfolio and ranks #1809 among its holdings. This is a return to the name: Steven Cohen previously reported a position in CRVS as recently as Q4 2025.

Steven Cohen first reported a position in CRVS in Q1 2017 and has held it in 14 quarters since. The position peaked at $47.6M in Q3 2025. 176 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

  • Steven Cohen held 435,146 shares of Corvus Pharmaceuticals worth $5.01M as of Q3 2026.
  • Corvus Pharmaceuticals was a new Steven Cohen position in Q3 2026.
  • Corvus Pharmaceuticals made up 0.01% of Steven Cohen's portfolio in Q3 2026, its #1809 holding.
  • Steven Cohen first reported a position in Corvus Pharmaceuticals in Q1 2017 and has held it in 14 quarters since.
  • Steven Cohen's Corvus Pharmaceuticals position peaked at $47.6M in Q3 2025.
  • 176 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on Point72 Asset Management's 13F filing for Q3 2026, filed 16 Nov 2026.